Synlogic, Inc.: peers
Synlogic, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Synlogic, Inc., Aligos Therapeutics, Inc., Provectus Biopharmaceuticals Inc., Alaunos Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Synlogic, Inc.base SYBX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Kalaris Therapeutics, Inc. KLRS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Aligos Therapeutics, Inc. ALGS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Biomea Fusion, Inc. BMEA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Instil Bio, Inc. TIL · 🇺🇸 US Percentile in Healthcare Percentile in USA | Provectus Biopharmaceuticals Inc. PVCT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Alaunos Therapeutics, Inc. TCRT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Tevogen Inc. TVGN · 🇺🇸 US Percentile in Financial Services Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $44 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $45 MOct 26, 2026 · Market data6th of 8 | $43 MAug 1, 2026 · Market data8th of 8 | $45 MOct 30, 2026 · Market data5th of 8 | $46 MOct 29, 2026 · Market data3rd of 8 | $46 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8 | $47 MAug 1, 2026 · Market data1st of 8 | $47 MOct 14, 2026 · Market data2nd of 8 | $46 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | $2 MFY2025 · SEC1st of 3 | —— | —— | $0 MFY2025 · SEC2nd of 3 | $0 MFY2025 · SEC3rd of 3 | —— | $0 M3 ranked |
| Net income (Higher is better) | $-1 MFY2025 · SEC1st of 8 | $-43 MFY2025 · SEC6th of 8 | $-24 MFY2025 · SEC4th of 8 | $-62 MFY2025 · SEC7th of 8 | $-71 MFY2025 · SEC8th of 8 | $-5 MFY2025 · SEC3rd of 8 | $-4 MFY2025 · SEC2nd of 8 | $-26 MFY2025 · SEC5th of 8 | $-25 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | 107As on 2021 · Profile1st of 3 | 67As on June-2020 · Profile2nd of 3 | 41December 31, 2025 · Profile3rd of 3 | —— | —— | —— | —— | 673 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | -35.5%30 days to Oct 26, 2026 · Market data2nd of 2 | —— | —— | -4.0%30 days to Oct 29, 2026 · Market data1st of 2 | —— | —— | —— | -19.7%2 ranked |
| Revenue growth (Higher is better) | ———— | ———— | -39.3%FY2025 · SEConly one with it5th2nd | ———— | ———— | ———— | ———— | ———— | -39.3%— |
| Margins and returns | |||||||||
| Return on equity (Higher is better) | -8.1%FY2025 · SEC1st of 568th34th | ———— | -196.9%FY2025 · SEC4th of 511th5th | -152.4%FY2025 · SEC3rd of 516th7th | -50.8%FY2025 · SEC2nd of 543rd18th | ———— | -198.6%FY2025 · SEC5th of 511th4th | ———— | -152.4%5 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 19.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | 0.6×price Oct 26, 2026 · Market data2nd of 38th8th | 0.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 1.5×price Oct 30, 2026 · Market data1st of 331st37th | 0.4×price Oct 29, 2026 · Market data3rd of 35th5th | ———— | 21.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 0.6×3 ranked |
| Free cash flow yield (Higher is better) | ———— | -86.6%price Oct 26, 2026 · Market data2nd of 39th3rd | -188.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -121.0%price Oct 29, 2026 · Market data3rd of 35th2nd | ———— | -6.3%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -26.6%price Oct 14, 2026 · Market data1st of 35th12th | -86.6%3 ranked |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | -32.0×FY2025 · SEC2nd of 325th12th | ———— | ———— | -13.5×FY2025 · SEC1st of 339th19th | -529.0×FY2025 · SEC3rd of 35th2nd | ———— | ———— | -32.0×3 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 3 of 8FY2025 · Scorecard1st of 8 | 3 of 11FY2025 · Scorecard2nd of 8 | 2 of 10FY2025 · Scorecard5th of 8 | 2 of 11FY2025 · Scorecard6th of 8 | 2 of 12FY2025 · Scorecard7th of 8 | 2 of 8FY2025 · Scorecard3rd of 8 | 2 of 8FY2025 · Scorecard3rd of 8 | 0 of 8FY2025 · Scorecard8th of 8 | 23% passed8 ranked |
| Valuation checks (Higher is better) | —— | 1 of 4FY2025 · Scorecard2nd of 4 | —— | 1 of 3FY2025 · Scorecard1st of 4 | 1 of 4FY2025 · Scorecard2nd of 4 | —— | —— | 0 of 4FY2025 · Scorecard4th of 4 | 25% passed4 ranked |
| Growth checks (Higher is better) | 1 of 2FY2025 · Scorecard1st of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 1 of 3FY2025 · Scorecard5th of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 0 of 2FY2025 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard6th of 8 | 42% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard1st of 8 | 0% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 2FY2025 · Scorecard1st of 8 | 1 of 3FY2025 · Scorecard5th of 8 | 1 of 3FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard7th of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard7th of 8 | 42% passed8 ranked |
| Shareholder returns checks (Higher is better) | 1 of 1FY2025 · Scorecard1st of 7 | —— | 0 of 1FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 0.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 72.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 24.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 36.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 28.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | —— | 6.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 1.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 24.9%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | 12026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 542026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | —— | 322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 327 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -0.0 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | -5.8 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | —— | +1.2 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | -6.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | —— | -1.7 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | -1.6 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | -1.7 pp6 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Synlogic, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kalaris Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aligos Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biomea Fusion, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Instil Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Provectus Biopharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alaunos Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tevogen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Revenue growth#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Revenue growth | In its sector | In its country |
|---|---|---|---|
| Synlogic, Inc. | — | — | — |
| Kalaris Therapeutics, Inc. | — | — | — |
| Aligos Therapeutics, Inc. | -39.3%FY2025 | 5th percentile in Healthcaremedian +10.2%, 734 companies | 2nd percentile in USAmedian +6.5%, 3,424 companies |
| Biomea Fusion, Inc. | — | — | — |
| Instil Bio, Inc. | — | — | — |
| Provectus Biopharmaceuticals Inc. | — | — | — |
| Alaunos Therapeutics, Inc. | — | — | — |
| Tevogen Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Synlogic, Inc. | Kalaris Therapeutics, Inc. | Aligos Therapeutics, Inc. | Biomea Fusion, Inc. | Instil Bio, Inc. | Provectus Biopharmaceuticals Inc. | Alaunos Therapeutics, Inc. | Tevogen Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $2 MSEC1st | — | — | $0 MSEC2nd | $0 MSEC3rd | — |
| 2024 | $0 MSEC3rd | — | $4 MSEC1st | — | — | $1 MSEC2nd | $0 MSEC3rd | — |
| 2023 | $3 MSEC2nd | — | $6 MSEC1st | — | — | $1 MSEC3rd | $0 MSEC4th | — |
| 2022 | $1 MSEC2nd | — | — | — | — | $1 MSEC3rd | $3 MSEC1st | — |
| 2021 | $2 MSEC1st | — | — | — | — | — | $0 MSEC2nd | — |
| 2020 | — | — | — | — | $0 MSEC | — | — | — |
| 2019 | $2 MSEC1st | $0 MSEC2nd | — | — | — | — | — | — |
| 2018 | $3 MSEC1st | — | — | — | — | — | $0 MSEC2nd | — |
| 2017 | $2 MSEC2nd | — | — | — | — | — | $16 MSEC1st | — |
| 2016 | — | — | — | — | — | — | $7 MSEC | — |
| 2012 | — | — | — | — | — | — | $1 MSEC | — |
| 2011 | — | — | — | — | — | — | $1 MSEC | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Synlogic, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Kalaris Therapeutics, Inc.KLRS · 🇺🇸 USASame industry: Biotechnology · Similar size: $45 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $45 M (Oct 26, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Aligos Therapeutics, Inc.ALGS · 🇺🇸 USASame industry: Biotechnology · Similar size: $43 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $43 M (Aug 1, 2026) · revenue $2 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Biomea Fusion, Inc.BMEA · 🇺🇸 USASame industry: Biotechnology · Similar size: $45 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $45 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Instil Bio, Inc.TIL · 🇺🇸 USASame industry: Biotechnology · Similar size: $46 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $46 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Provectus Biopharmaceuticals Inc.PVCT · 🇺🇸 USASame industry: Biotechnology · Similar size: $46 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $46 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Alaunos Therapeutics, Inc.TCRT · 🇺🇸 USASame industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $47 M (Aug 1, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Tevogen Inc.TVGN · 🇺🇸 USASame industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $47 M (Oct 14, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Veru Inc.VERU · 🇺🇸 USASame industry: Biotechnology · Similar size: $41 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $41 M (Oct 9, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- INmune Bio, Inc.INMB · 🇺🇸 USASame industry: Biotechnology · Similar size: $48 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48 M (Oct 23, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Werewolf Therapeutics, Inc.HOWL · 🇺🇸 USASame industry: Biotechnology · Similar size: $48 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48 M (Oct 27, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Forum Markets, IncorporatedFRMM · 🇺🇸 USASame industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $47 M (Oct 26, 2026) · revenue $7 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Dogwood Therapeutics, Inc.DWTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $49 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $49 M (Oct 15, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.